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Abstract
Background: Well-characterized mice models will afford a cheaper, easy-handling opportunity for a more
comprehensive understanding of 2009 influenza A (H1N1) virus’s pathogenesis potential. We aimed to provide a
robust description of pulmonary immune responses in the mice infected by the virus.
Methods: BALB/c mice were inoculated intranasally with A/Beijing/501/2009(H1N1) (BJ501) and A/PR/8/34(H1N1)
(PR8) viruses and compared for survival rate, viral replication, and kinetics of pulmonary immune responses.
Results: BJ501 virus replicated less efficiently in the lungs than PR8, and both caused lethal illness in the mice. The
transient increases of pulmonary TNF-α 2 days post infection for BJ501 and of INF-γ and IL-10 at 6 days post infection
for PR8 were observed. IL-2+ and IL-4+ secreting cells showed significant increase 12 days post infection, while IFN-γ+,
IgG+ and IgA+ secreting cells increased 6 days post infection. The different patterns of pulmonary immunological
parameters between two viruses were at most seen in IL-6, IL-17 secretion and IgG1/IgG2a ratio.
Conclusions: The BALB/c mouse is evaluated as a good pathogenic model for studying BJ501 2009 H1N1 virus. The
work provided some basic and detailed data, which might be referred when further evaluating innate and adapted
pulmonary immune responses and local viral load in mice.
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Background
During March and early April 2009, a sharp increase in
patients with influenza-like illness and associated hospi-
talizations and deaths in several areas of Mexico was no-
tified, which was later proved to be caused by a novel
swine origin 2009 influenza A (H1N1) virus (2009
H1N1) [1]. The virus was first identified in April from
two unrelated pediatric febrile patients in southern
California [2]. Genetic analysis demonstrated the 2009
H1N1 virus contained a unique combination of gene
segments from both North American and Eurasian
swine lineages that has not been identified previously in
either swine or human populations [3]. By August 1,
2010, almost every country had reported laboratory con-
firmed cases, with over 18449 total death [4].
The main concerns about a new influenza pandemic
are the disease burden and associated mortality it may
cause. These are largely due to pneumonia resulting
from viral infection. Many 2009 H1N1 infected patients
have required hospitalization because of severe pneumo-
nia and respiratory failure, with a fatal outcome [5]. Pre-
vious study indicated that 2009 H1N1 virus replicated
efficiently in the mice lungs and resulted lesions in the
lung histologically [6-8]. These suggest the mice model
might be proper for 2009 H1N1 virus infection without
mouse adaptation.
2009 H1N1 virus has many different properties on its
replication and induced pulmonary immune responses
in the lungs. 2009 H1N1 virus caused more severe pul-
monary lesion than seasonal influenza viruses in animals
[8,9]. In addition, the lower glycan binding properties
also seemed to correlate with less-efficient transmission
of 2009 H1N1 viruses in ferrets compared to seasonal
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H1N1 viruses [8]. In addition, the pathogenesis of lung
lesions caused by 2009 H1N1 viruses might be different
from 1918 pandemic virus and highly pathogenic avian
influenza H5N1 virus, as no major “cytokine storm” was
observed with 2009 H1N1 infection of the human cell
lines [10,11] and the mice lungs [6]. This lower cytokine
production of 2009 H1N1 virus infection compared to
1918 virus and H5N1 virus might be associated with the
findings that the virus did not spread to extrapulmonary
organs and caused no viremia in ferrets or mice [8,9].
Also, 2009 H1N1 virus differs in modest but subtle ways
from seasonal influenza virus for cytokine dysregulation
in vitro and in ex vivo cultures of human cell lines [10-12].
Thus, we want to study 2009 H1N1 virus pulmonary
infection in the mice to provide a raw data on the Th1/
Th2 cellular immune responses and IgG, IgA, IgM, and
IgG subtype antibodies humoral immune responses at
different days post infection.
Methods
Viruses
A virulent strain of influenza A virus, A/PR/8/34
(H1N1) (PR8), was kindly provided by Dr. Yuelong-Shu
(Chinese Center for Disease Control and Prevention).
Influenza H1N1 A/Beijing/501/2009(BJ501) virus was
isolated and obtained from our institution. Virus stocks
were propagated consistent with the original isolate pas-
sage in the allantoic cavity of 10-day-old embryonated
hens’ eggs. Each egg was injected with 0.1 ml normal sa-
line containing 1 haemagglutinin unit (HAU) of virus,
incubated for 48 h at 34°C, and then held at 4°C over-
night. The allantoic fluids were harvested, pooled, centri-
fuged to remove cellular debris and stored at −70°C
until use. Virus stocks were low-passage-number viruses
(E1-E2). For some assays, virus stock was further puri-
fied by centrifugation through a discontinuous sucrose
gradient at 30,000 × g for 3 h at 4°C. The milky virus
band located in the upper half of the gradient was har-
vested, washed in phosphate-buffered saline (PBS), and
centrifuged at 24,000 × g for 4 h at 4°C. The virus pellet
was gradually re-suspended in PBS, and aliquots were
stored at −70°C. Virus stocks were quantified by a haem-
agglutination assay to obtain HAU. TCID50 was deter-
mined by titration in Madin-Darby canine kidney
(MDCK) cells, with daily observation of cytopathic ef-
fect, and confirmed by haemagglutination assays. Viral
titers were titrated by standard plaque assays in MDCK
cells as previous described for determination of PFU ti-
ters [13]. MDCK cells routinely maintained in Dulbec-
co’s Modified Eagle’s medium plus 10% fetal bovine
serum (FBS). The 50% egg infectious dose (EID50) was
determined by serial titration of virus stock in eggs, and
EID50/ml values were calculated according to the method
of Reed and Muench [14]. All animal experiments with
2009 H1N1 viruses were conducted under biosafety level
3 enhanced (BSL3+) containment in accordance with
guidelines of the World Health Organization [15].
Infection of mice
Female BALB/c mice (Institute of Jingfeng Medical
Laboratory, Beijing, China), 6 to 8 weeks of age, were
anesthetized with diethyl ether and inoculated intrana-
sally (i.n.) with 25 μl of infectious virus diluted in sterile
phosphate-buffered saline (PBS). Fifty-percent lethal
dose (LD50) titers were determined by the inoculating
groups of 6 mice i.n. with serial 10-fold dilutions of
virus. LD50 titers were calculated by the method of Reed
and Muench [14]. For determination of lung virus titers,
morbidity (measured by weight loss), and mortality at
multiple time points during the two weeks of infection,
30 additional mice were infected i.n. with inoculating
dose (5 × 105, 5 × 104 and 5 × 103 p.f.u.) of virus. Individ-
ual body weights from six mice were recorded for each
group on days 0, 2, 4, 6, 8, 10, 12 and 14 post infections
(p.i.) and monitored daily for disease signs and death for
14 days p.i. On days 2, 4, 6, 8, 10, 12 and 14 p.i., fifteen
mice with inoculating dose (5 × 105 p.f.u.) of virus at
each time point were euthanatized, lungs were collected
separately and homogenized in 2 mL sterile PBS. After
this process, homogenates were frozen separately in ster-
ile tubes at −80°C for later titration of virus loads, anti-
body detection and cytokine determination. For the
detection of lung immune cells and ELISPOT assay,
eight to ten mice at each time point post infection were
sacrificed by cervical dislocation. Single-cell suspensions
of the lungs were prepared as follows. Freshly resected
lungs were placed into cold DMEM, grinded gently and
the suspensions were pelleted, resuspended and passed
through nylon mesh filters. Red blood cells were re-
moved by lysis buffer treatment (BD biosciences). Cells
were counted and resuspended at appropriate concen-
trations for each particular experiment. The animal ex-
periments were approved by the Animal Subjects
Research Review Board of the Beijing Institute of Micro-
biology and Epidemiology and were conducted accord-
ing to the institution's guidelines for animal husbandry.
Real-time reverse-transcriptase-polymerase-chain-reaction
(RT-PCR) detection of the viral load
The viral load in the lungs was determined by real time
RT-PCR. RNA was extracted from the lungs by hom-
ogenizing with Trizol (Invitrogen, USA) reagent. Then,
reverse transcription was performed by targeting a con-
served region of the influenza matrix (M) gene for PR8
as previously described [16]. For the detection of BJ501,
the primers and probe were designed according to the
CDC protocol for swine influenza A virus [17].
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Flow cytometry
The lungs were harvested at various time points post
infection. Single cell suspensions were stained with
fluorochrome-labeled anti-CD3, anti-CD4, anti-CD8,
anti-CD11b, and anti-CD11 cantibodies (BD Biosci-
ences). Cells were labeled for 45 min at 4°C in staining
buffer (PBS with 1% FBS, 0.02% NaN3) and then washed
twice with PBS, and fixed overnight at 4°C with 2% para-
formaldehyde. Flow cytometry was performed on a
FACS Aria flow cytometer (BD Biosciences). The fre-
quency of neutrophils (CD11b+/CD11c-/Ly6G/c+) was
determined by appropriate gating within the total lung
leukocytes. For determination of frequency of CD4+T cells
and CD8+T cells, the CD3+T cells were first determined
by appropriated gating within the pulmonary lymphocytes,
and then CD4+/CD8−T cells and CD4−/CD8+T cells were
detected by gating within the CD3+T cells.
ELISPOT (enzyme-linked immunospot) assay for Cytokine
Secreting Cells (CSCs)
An ELISPOT assay was conducted as previously de-
scribed [18]. Briefly, ELISPOT 96-well plates (Millipore)
were coated with anti-mouse IFN-γ, IL-2, and IL-4 cap-
ture antibody and incubated for 24 h at 4°C (BD Biosci-
ences). The following day, the plates were washed and
blocked with 200 μL of 1640 medium containing 10%
fetal calf serum for 2 hours at room temperature to de-
crease the number of remaining protein-binding sites.
Two hundred thousand cells of lung cell suspensions
were added to each well and stimulated overnight at 37°C
in 5% CO2 in the presence of RPMI 1640 (negative con-
trol), Con A (positive control), purified PR8 or BJ501 an-
tigens (2.5 μg/ml). After 24 h of stimulation, the cells
were washed and incubated for 24 h at 4°C with biotinyl-
ated anti-mouse IFN-γ, IL-2 and IL-4 antibodies (BD Bio-
sciences). The plates were washed, and streptavidin-
alkaline phosphatase (BD Biosciences) was added to each
well and incubated for 2 h at room temperature. The
plate was washed, 100 μl of AEC solution (BD Biosci-
ences) were added to each well. The plate was then rinsed
with distilled water and dried at room temperature. Spots
were counted by an automated ELISPOT reader (CTL
Limited).
ELISPOT assay for Antibody Secreting Cells (ASCs)
The numbers of influenza-virus-specific Antibody-
Secreting Cells were determined using the ELISPOT
assay, as described previously [19]. Briefly, a 96-well
plate with a nitrocellulose base (Millititer HA; Millipore)
was coated with 2.5 μg/ml purified PR8 or BJ501 anti-
gen, as an irrelevant-antigen control, wells were coated
with phosphate-buffered saline containing 7.5 μg/mL
BSA, then blocked with 200 μL of 1640 medium con-
taining 10% fetal calf serum. A total of 5 × 106/ml cell
suspensions from the lungs were added to each well and
the mixture incubated for 9 h. The plate was washed
with PBS–Tween and incubated with goat anti-mouse
IgA (eBionsciences) or goat anti-mouse IgG (BD Biosci-
ences) conjugated with biotin. Then, streptavidine conju-
gated with alkaline phosphatase (BD Biosciences) was
added to each well and the plates were incubated for
1 hour at room temperature. The plates were washed as
before with PBS-T and PBS and 100 μl/well of AEC solu-
tion were added. The reaction was stopped after 10–30
minutes at room temperature in dark by thorough rins-
ing with a tap water. Spots were counted by an auto-
mated ELISPOT reader (CTL Limited).
Antibody assays
Influenza-specific pulmonary IgA, IgM and IgG isotypes
antibodies were measured by enzyme-linked immuno-
sorbent assay (ELISA), using plates coated with 1 μg/ml
per well of purified PR8 or BJ501 influenza virus. The re-
actions were detected by goat anti-mouse IgA, IgM
(Invitrogen), goat anti-mouse IgG1, IgG2b, IgG2a,
IgG2c, and IgG3 (Bethyl laboratories, Inc.), goat anti-
mouse IgG (Jackson ImmunoResearch Laboratories)
antibodies conjugated to horseradish peroxidase. The
plates were developed with TMB (Sigma, USA). Absorb-
ance was read at 450 nm on a Bio-RAD model 550 Mi-
croplate Reader. The virus-specific Ab titer was defined
as the reciprocal of the highest sample dilution giving an
absorbance value greater than twice that of the samples
from the negative controls. The titers were gained in
duplicate.
Cytokine measurement
The lungs were homogenized on ice individually in 2 ml
PBS. Cytokine protein levels were measured by a specific
ELISA assay following the kit description (R&D Systems,
Minneapolis, MN, USA). The detection limits for the
ELISA development kits are as follows: IFN-γ, 15-10000 pg/
mL; TNF-α, 15-10000 pg/mL; IL-6: 15-10000 pg/mL; IL-17:
15-10000 pg/ml; IL-10, 15-2000 pg/mL.
Statistical analysis
Statistical differences at each time point within one
group were determined by one-way ANOVA test, while
statistical differences of the two viruses at the same
time-point were determined by independent-sample T
Test with SPSS19.0. Values of p<0.05 were considered
significant.
Results
Comparisons of survival rate, weight loss and viral load in
the mice
In this study, we used the same infectious doses of two in-
fluenza viruses, although the LD50 was different between
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PR8 viruses and BJ501 viruses (the LD50 of PR8 was 5.0 ×
103 p.f.u/25 μL while BJ501 was 7.76 × 103 p.f.u/25 μL
respectively). Three doses (5 × 105, 5 × 104 and 5 × 103
p.f.u. i.n.) were initially used and the lower groups (5 ×
103, 5 × 104) showed a significant higher survival rate in
BJ501 infections than in PR8 ones (data not shown). No
significant differences of survival rate and weight lose were
observed in high (5 × 105) dose infection (Figure 1A, B),
and this dose was used in the following infections. The de-
crease of viral load was significantly earlier in the lungs of
Figure 1 Virulence of two strains of influenza A virus on mice. BALB/c mice were intranasally infected with 5 × 105 p.f.u. dose of A/Beijing/
501/2009 (H1N1) and A/PR/8/34 (H1N1) viruses. (A) Survival data and (B) Weight loss (C) Viral growth in the lung at different time points. Viral
loads were determined in homogenates prepared from lungs at certain time points post-infection by real time RT-PCR test, and were expressed
as viral RNA copies per miligram lung tissue. Mean viral load is representative of 5–6 mice lungs per time point group, and I bars indicated the
standard deviations. The dotted lines were the control level. $ p < 0.05, compared among different time-points within BJ501 viruses infection,
# compared among different time-points within PR8 viruses infection, *p < 0.05 and **p < 0.01, compared between BJ501 and PR8 infections at
the same time-point.
Figure 2 The kinetics of pulmonary immune cells responses induced by influenza virus infection. Mice without infection were used as the
control group. Mean cell numbers were representative of 3 mice lungs per time point group, and I bars indicated the standard deviations. The
dotted lines were the control level. $ p < 0.05, compared among different time-points within BJ501 viruses infection, # compared among different
time-points within PR8 viruses infection, *p < 0.05 and **p < 0.01, compared between BJ501 and PR8 infections at the same time-point.
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mice infected with BJ501 viruses (from day 10 post infec-
tion) than that in the PR8 infection (from day 12 post in-
fection). On the other hand, pulmonary viral load was
significantly higher in PR8 infection than in BJ501 group
(Figure 1C) (p < 0.05).
The kinetics of pulmonary immune cell responses and
cytokine productions in the mice
As expected, total pulmonary cells accumulated 6 days
post infection in local in both virus infections (Figure 2).
The neutrophils significantly increased as early as 2 days
post infection with BJ501, and this increasing was 4 days
earlier than that of PR8 infection (Figure 2). The in-
crease of CD4+T cells was only observed in the late
infection with both viruses (14 days p.i.) (Figure 2). A
transient increase of CD8+T cells at 2 days post infection
with BJ501 was observed, but CD8+T cell decreased to
normal level until days 14 (Figure 2). Pulmonary cyto-
kine excretions were seen in Figure 3. In the BJ501 in-
fection group, TNF-α increased significantly on days 2
but dropped to control level immediately in the follow-
ing days. IL-6 increased from days 2 to days 6 and from
days 12 to days 14 post infection. Both IFN-γ and IL-10
did not significantly change during the whole infection.
However, IL-17 significantly decreased from 4 to 6 days
and then recovered to control level on days 8 post infec-
tion (Figure 3). Otherwise, in the PR8 infection group,
IFN-γ, and IL-10 transiently increased at days 6 post
Figure 3 Determination of cytokine levels in the lungs of mice per time-point with influenza virus infection. Five to six mice were
euthanized at each time point post infection, and lung homogenates were generated for analysis. IL-6, TNF-α, IFN-γ, IL-10, and IL-17 levels were
assayed by ELISA as described in Methods. Mice without infection were used as the control group. Columns represented mean cytokine concen-
trations representative of 5–6 mice, and I bars indicated the standard deviations. The dotted lines were the control level. $ p < 0.05, compared
among different time-points within BJ501 viruses infection, # compared among different time-points within PR8 viruses infection, *p < 0.05 and
**p < 0.01, compared between BJ501 and PR8 infections at the same time-point.
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infection, and then both decreased to control level in the
late stage of infections. The earliest cytokine noted was
IL-6, which increased at 2 days, then dropped to control
level at 6 days post infection. IL-17 however, showed sig-
nificantly decreased level during the infection, especially
after 2 days post infection (Figure 3).
Antibody responses in the lung of mice
Figure 4A illustrated that IgA, IgM, and IgG antibodies all
increased significantly during the infections. The isotype
analysis showed IgG isotype had a similar dynamic pattern
between two groups. Both IgG1, IgG2b, IgG2a and IgG3
subpopulation increased simultaneously, and IgG1and
IgG2b were predominant. The level of IgG3 antibody ti-
ters was similar to that of IgG2a. No detectable IgG2c was
found in this study (data not shown). In BJ501 infection
group, the increase of IgG1 was 4 days earlier than that of
IgG2a (Figure 4B). On days 14, the titers of IgG1 and
IgG2a were 1:16218 and 1:5012 respectively. In PR8
group, both IgG1 and IgG2a increased significantly on
days 8, and kept at high level till 14 days post infection,
and the titers were 1:2512 and 1:794 respectively
(Figure 4B). Data in Figure 4B illustrated that the ratio of
IgG1 to IgG2a in the BJ501 group was higher than that in
the PR8 group in the early infection, which suggested a
stronger Th2 response predominance in the BJ501 infection.
Figure 4 Kinetics of antibody responses in the lungs of mice with influenza virus infection. Kinetics of IgA, IgM, IgG, (A) and IgG2a, IgG1
antibody responses and IgG1/IgG2a ratio (B) in the lungs of mice after 5 × 105 p.f.u. A/Beijing/501/2009(H1N1) and A/PR/8/34/(H1N1) viruses
infection. Mice were sacrificed at certain time points post infection, and virus-specific antibodies in the lungs were determined by ELISA. Mice
without infection were used as the control group. I bars represent standard deviations. The dotted lines were the control level. $ p < 0.05,
compared among different time-points within BJ501 viruses infection, # compared among different time-points within PR8 viruses infection,
*p < 0.05 and **p < 0.01, compared between BJ501 and PR8 infections at the same time-point.
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Influenza virus-specific CSCs and ASCs responses in the
lungs of mice
The cytokines (IFN-γ+, IL-2+, IL-4+) secreting cells
(CSC) and antibody (IgG+ and IgA+) secreting cells
(ASCs) to influenza virus antigens in the lungs of mice
were investigated by the ELISPOT assay. We found that
IFN-γ+ CSC response was highest and its pattern was
similar between two viruses, although by the end of ob-
servation IFN-γ+ CSC response in the BJ501 were much
higher than that in the PR8 infection (548.54 and 290.23
CSCs per 105 cells respectively). The response level and
peak day of IL-2+ and IL-4+ CSCs induced by the BJ501
showed a little difference from those by the PR8
(Figure 5A). Figure 5B showed that IgG+ ASCs to influ-
enza BJ501 antigens was similar with that to PR8 from
days 6 to days 12 post infection, but on days 14, BJ501
group showed significant higher response than PR8 one
(Figure 5B). IgA+ ASCs in the BJ501 group increased sig-
nificantly on days 8, then dropped slightly on days 10
but was still significant higher than that in the control
and then kept increasing from days 12 to days 14 post
infection. In contrast, the level of IgA+ ASCs in the PR8
group increased significantly in the early stage of infec-
tion, then dropped to control level immediately from
days 4 to days 8, and on days 10 it increased a little, and
kept at control level from days 12 to 14 (Figure 5B).
Discussion
To evaluate effective therapies and elucidate influenza
pathogenesis, it is essential to have laboratory animal
Figure 5 Influenza virus-specific CSCs and ASCs responses in the lungs of mice with influenza viruses infection. Influenza virus-specific
cytokine secreting cells (CSCs) (A) and antibody secreting cells (ASCs) (B) responses in the lungs of mice with 5 × 105 p.f.u. A/Beijing/501/2009
(H1N1) and A/PR/8/34/(H1N1) viruses infection. Quantitative analysis of influenza-specific CSCs (IFN-γ+, IL-4+ and IL-2+) and ASCs (IgG+ and IgA+) was
done with ELISPOT assay. I bars represent standard deviations. The dotted lines were the control level. $ p < 0.05, compared among different time-
points within BJ501 viruses infection, # compared among different time-points within PR8 viruses infection, *p < 0.05 and **p < 0.01, compared
between BJ501 and PR8 infections at the same time-point.
Lv et al. BMC Infectious Diseases 2014, 14:197 Page 7 of 11
http://www.biomedcentral.com/1471-2334/14/197
models that replicated the major features of illness in
human. The animal models currently in use for influ-
enza include mice, ferrets, rats [20], pigs [21], cats [22],
dogs [23], and nonhuman primates [24]. Mice and fer-
rets are currently the most intensively employed models,
and mice remain the primary model due to their cost,
inbreeding, and ability to utilize genetically modified ani-
mals. Influenza-virus-infected ferrets develop many of
the typical signs of infection in humans [25]. The limita-
tions of the ferret model are the lack of specific reagents
in studying immune system and the availability of ani-
mals without prior exposure to influenza [26]. Our study
demonstrated that 2009 H1N1 virus replicated efficiently
in the lung of mice, and for severe infections and for le-
thal mice experiment as in this study, a high viral load
might be present, and 2009 H1N1 virus seemed to in-
duce a distinct pattern of cytokine markers associated
with the pathogenesis.
The most outstanding cytokine is IL-6. Its correlation
with severe infections of 2009 H1N1 virus was demon-
strated in both human cases [27,28] and in high dose in-
oculated mice model [7]. In our mice experiment, we
found IL-6 significantly increased not only in the early
but also in the late stage of infection. IL-6, a multifunc-
tional cytokine expressed by both lymphoid and non-
lymphoid cells [29], played a central role in resolving the
innate immune response and directing the transition
from innate to adaptive immunity [30], and IL-6 concen-
trations were significantly correlated with the symptoms
and signs of influenza A infection in human [31,32],
whereas depletion of IL-6 did not directly protect against
death from lethal H5N1 influenza virus infection [33].
Recently, IL-6 is found to be in the regulation of Th17
differentiation [34]. Th17 cell also secrets cytokine of IL-
17, which is critical in the immunopathology of acute
lung injury due to acute influenza infection [35].
However, the in vivo role of IL-17 in the clearance of
influenza virus and its immune pathology has been con-
troversial. Several studies have demonstrated the import-
ant protective role of IL-17 against lethal influenza
infection. In contrast, other groups have showed that IL-
17 signaling was not required for viral clearance, but ra-
ther played a pathogenic role by recruiting neutrophils
to the site of inflammation [27,36-38]. Furthermore, IL-
17 deficiency or treatment with monoclonal antibodies
against IL-17-ameliorated acute lung injury induced by
the 2009 H1N1 virus in the mice [39]. In our mice ex-
periment, we found significant decreased pulmonary IL-
17 both in BI501 and PR8 infection, whether this corre-
lated with the virus replication in local deserved further
study.
TNF-α is an important proinflammatory cytokine lo-
cated at the downstream of IL-17. Previous study found
it also had a positive feedback effect on Th17 in vitro
Table 1 Amino acid differences among BJ 501, Cal 04 and PR 8 influenza viruses
Gene Mutation Effect Strains* Reference
BJ 501 Cal 04 PR8
PB2 E627K −627 K associated with increased transmission, advantageous replication at 33°C and confers
air transmission of avian virus.
E E K [53]
-Important determination of host range. Avian strains have 627E, human strains 627 K.
-627 K is linked to increased virulence in mice.
PA S224P Unknown S P S
P275L Unknown L L P
NS1 P42S −42S is critical for virulence of H5N1 strains and to antagonize host cell interferon induction S S S
HA A227E Unknown E E A
P83S Unknown S P P
A197T Unknown A T A
I321V Unknown V I I
NP D16G Unknown G G D
V100I Unknown I V V
NA H274Y -Oseltamivir resistance is associated to H274Y Y Y S
I106V Unknown I V I
D248N Unknown D N D
M2 S31N -Confers cross-resistance to adamantane drugs N N N
M1 L42F Unknown F L L
D94N Unknown N D D
*BJ501, A/Beijing/501/2009(H1N1); Cal04, A/California/04/2009(H1N1); PR8, A/PR/8/34(H1N1).
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[40]. The transient increase of TNF-α at days 2 might
contribute in the enhancement of chemokine gene ex-
pression, macrophages and dendritic cells maturation,
and further activation of antigen presentation [41]. TNF-
α level has been found to correlate directly with the
severity of gross and histologic lung lesions in the influ-
enza infected mice [42]. Daniela Damjanovic and his col-
leagues suggested that TNF-α was dispensable for
influenza clearance. Their study showed that TNF-α was
up-regulated in the lung after influenza infection and
TNF-α deficiency led not only to a greater extent of ill-
ness but also to heightened lung immunopathology and
tissue remodeling [43]. Taken together, proinflammatory
cytokine (TNF-α) and mediators involved in the devel-
opment of Th17 (IL-17, IL-6) responses were associated
with the critical illness of 2009 pandemic influenza in-
fection either in the detrimental or beneficial role. The
IL-6 pathway had been a promising new therapeutic tar-
get in treatment of autoimmune illness [44,45]. The use
of anti-inflammatory and immunomodulatory agents for
pandemic influenza control should be largely evaluated
in case of antiviral resistance [46].
Several studies had indicated that the increased patho-
genicity of influenza A virus may be associated with
extremely rapid recruitment of macrophages and neutro-
phils into the lungs in fatal infection [47,48]. In addition,
in the late recovery phase, macrophage and neutrophils
may be in primary cooperation with the antibody
working at the late-phase clearance of influenza virus
through phagocytic elimination of infected cells [49,50].
Contrast to IFN-γ+ CSCs increasing from the early in-
fection, IL-2+ and IL-4+ CSCs only increased 12 days
post infection, which implied the strongly stimulated
adapted immune response. In addition, we found that
BJ501 virus also induced relatively stronger Th2 medi-
ated responses (pulmonary IgA+ and IgG+ secreting
cells, IgG2/IgG2a ratio) in the lung than PR8 virus.
These stronger Th2 immune responses might be corre-
lated with the relatively less efficient virus replication in
the lung.
The analysis of known molecular determinants that
confer pathogenicity and antiviral drug resistance in
2009 H1N1 viruses was previously discussed [3]. Viruses
with lysine at position 627 replicated better at 33°C, the
temperature found in the human upper respiratory tract
[51]. The mutations (HA, T197A; NA, V106I and N248D;
PA, P224S; NP, V100I) between BJ501 and Cal04 were
also found in A/Mexico/4482/09(H1N1) strain, which
was isolated from a fatal case [6]. The HA 227 substitu-
tion from alanine in PR8 to glutamic acid in BJ501 and
Cal04 was located in the glycan receptor-binding sites
and antigenic loops [52]. All these mutations (see
Table 1) should be further characterized of their func-
tional determinants.
Conclusions
Although the global wave of 2009 H1N1 virus has went
away, many unsolved questions are still important to be
further clarified for prevention and control of potential
pandemic threat. This study provided some basic data
on the optimal time to observe different immune param-
eters, for example, IL-2+, IL-4+ CSCs stimulated about
12 days post infection, TNF-α, IFN-γ, IL-10 cytokines
only transiently increased in the early infection. It is
hoped this paper will contribute for immunological re-
searchers to the better use of mice experiment to study
the correlation between the viral load and critical im-
mune response in the lung.
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